Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats
Authors:
- 25 November 2010
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 68 (2) , 531-538
Abstract
Purpose Leptomeningeal carcinomatosis is a devastating complication of malignant disease. In this study, we evaluated the safety and pharmacokinetics of intrathecally administered pemetrexed in rats. Methods Three levels of pemetrexed (0.3, 1, and 3 mg/kg) were administered to 15 rats per level (45 rats in total) twice a week for 2 weeks through specifically designed indwelling subarachnoid catheters. Presence of clinical and pathological neurotoxicity was evaluated. To evaluate the pharmacokinetics of pemetrexed, independent cohorts of 30 rats were treated with 1 mg/kg of pemetrexed and its concentration in cerebrospinal fluid (CSF) and blood was measured using UPLC/MS/MS. Results There were no cases of clinical or pathologic neurotoxicity after intrathecal administrations of pemetrexed at levels of 0.3 and 1 mg/kg; however, 5 of 15 (33%) rats died after administration of 3 mg/kg pemetrexed. The distribution/elimination of pemetrexed in CSF was best described by a two-compartment model, with initial and terminal half-lives of 0.43 and 1.43 h, respectively. The predicted maximal concentration in CSF was 588 μM, and high levels of pemetrexed appeared to be maintained for a long time. Area under the curve and volume of distribution at steady state were 560 μM h and 1.14 ml, respectively. Conclusions The no observed adverse effect level of intrathecal administration of pemetrexed was 1 mg/kg in rats. At this level, therapeutically high and durable pemetrexed concentrations could be achieved. Based on these results, further research on intrathecal pemetrexed in humans or non-human primates should be considered.Keywords
This publication has 28 references indexed in Scilit:
- Icariin isolated from Epimedium brevicornum Maxim attenuates learning and memory deficits induced by d-galactose in ratsPharmacology Biochemistry and Behavior, 2010
- Leptomeningeal metastases in the MRI eraNeurology, 2010
- Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib ErasOncology, 2009
- A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumoursBritish Journal of Cancer, 2006
- Distribution of the Novel Antifolate Pemetrexed to the BrainThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non–Small-Cell Lung Cancer CellsMolecular Pharmacology, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Review of a promising new agent-pemetrexed disodiumCancer, 2003
- NMDA-Antagonist MK-801-induced neuronal degeneration in Wistar rat brain detected by the Amino-Cupric-Silver methodExperimental and Toxicologic Pathology, 2003
- High‐dose leucovorin reverses acute high‐dose methotrexate neurotoxicity in the ratAnnals of Neurology, 1989